Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2009 Aug;10(8):1323-39. doi: 10.2217/pgs.09.53.

Pharmacogenomics of CYP3A: considerations for HIV treatment.

Author information

1
Department of Pharmaceutical Sciences, DYC School of Pharmacy, Buffalo, NY 14201 USA.

Abstract

The understanding of the cytochrome P450 3A SNP in antiretroviral therapy is important, because it is highly inducible, extremely polymorphic and metabolizes many of the drugs that are key components of highly active antiretroviral therapy regimens. This enzyme is prolific and promiscuous towards drug and xenobiotic substrate selection and it is also unpredictable among individuals, having a 5- to 20-fold variability in its ability to contribute to drug clearance. The importance of human CYP3A pharmacogenetics is also gaining attention in other established areas of pharmacotherapy as it may contribute to the goal of predicting efficacy and/or toxicity, specifically with the discovery of null allele CYP3A4*20. This review summarizes the current understanding, implications of genetic variation in the CYP3A enzymes, the central role of CYP3A in linking human genetics, the pharmacokinetics and resulting pharmacodynamic responses to certain antiretroviral drugs, and their eventual place in applied clinical pharmacotherapy.

PMID:
19663676
PMCID:
PMC2776626
DOI:
10.2217/pgs.09.53
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center